B Group, Inc. holds a focused book of 20 stocks worth $134.9M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened NRX Pharmaceuticals Inc and trimmed Apogee Therapeutics Inc. Their largest long position is Adma Biologics Inc at 21% of the equity book. Cloning the disclosed picks since 2025 would be +31% (+20.2%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2043476/holdings"
Use Arkolith to show B Group, Inc.'s latest holdings, largest changes, and filing provenance.
Following at the filing date actually beat the quarter-end book by 15.1 points over this window.
Growth of $10,000 cloning B Group, Inc.'s disclosed long 13F book, rebalanced on each filing date (so it reflects the ~45-day reporting lag, no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as B Group, Inc.
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 20 / 20 | $2.5B |
| MORGAN STANLEY | 20 / 20 | $642.6M |
| UBS Group AG | 20 / 20 | $258.1M |
| STATE STREET CORP | 19 / 20 | $1.2B |
| GEODE CAPITAL MANAGEMENT, LLC | 19 / 20 | $680.7M |
| BNP PARIBAS FINANCIAL MARKETS | 19 / 20 | $112.9M |
| BARCLAYS PLC | 19 / 20 | $35.9M |
| CITIGROUP INC | 19 / 20 | $15.4M |
Ranked by how many of B Group, Inc.'s top 20 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Adma Biologics Inc COM | $28.9M | 3.21M | 21.4% | ▲+31% Added · +750K sh | |
| 2 | Palisade Bio Inc COM | $20.0M | 11.41M | 14.8% | ▲+154% Added · +6.9M sh | |
| 3 | Praxis Precision Medicines I COM NEW | $10.7M | 33.2K | 7.9% | —Held | |
| 4 | Cellectis S A SPON ADS | $10.4M | 3.28M | 7.7% | —Held | |
| 5 | Zai Lab Ltd ADR | $8.5M | 450.6K | 6.3% | ▲+13% Added · +51K sh | |
| 6 | Taysha Gene Therapies Inc COM SHS | $8.0M | 1.80M | 6.0% | —Held | |
| 7 | NRX Pharmaceuticals Inc COM NEW | $6.4M | 3.00M | 4.7% | ▲New New position | |
| 8 | Structure Therapeutics Inc SPONSORED ADS | $6.1M | 127.5K | 4.6% | ▲+42% Added · +38K sh | |
| 9 | Iovance Biotherapeutics Inc COM | $5.3M | 1.50M | 3.9% | —Held | |
| 10 | Spyre Therapeutics Inc COM NEW | $5.0M | 100.0K | 3.7% | —Held | |
| 11 | Bright Minds Biosciences Inc COM NEW | $4.9M | 67.5K | 3.7% | ▲New New position | |
| 12 | Assembly Biosciences Inc COM NEW | $4.9M | 175.7K | 3.6% | —Held | |
| 13 | Aura Biosciences Inc COM | $4.0M | 597.6K | 3.0% | ▲+4.4% Added · +25K sh | |
| 14 | Oruka Therapeutics Inc COM | $3.7M | 75.0K | 2.7% | —Held | |
| 15 | Sight Sciences Inc COM | $3.7M | 970.0K | 2.7% | ▲+5.4% Added · +50K sh | |
| 16 | Ultragenyx Pharmaceutical In COM | $2.8M | 135.0K | 2.1% | —Held | |
| 17 | Apogee Therapeutics Inc COM | $631K | 7.5K | 0.5% | ▼−63% Reduced · −13K sh | |
| 18 | Foghorn Therapeutics Inc COM | $488K | 102.0K | 0.4% | ▲New New position | |
| 19 | Soleno Therapeutics Inc COM | $251K | 7.5K | 0.2% | ▲New New position | |
| 20 | Replimune Group Inc COM | $199K | 26.0K | 0.1% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 20 | $134.9M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 16 | $135.4M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 20 | $135.9M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 17 | $129.9M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 19 | $116.7M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 18 | $163.6M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.